| Monograph Title
| Section Head
| Scientific Liaison
|
| DANTROLENE SODIUM CAPSULES PF 33(4) Pg.
645 |
Dissolution <711> |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Title |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Chemical Info |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Definition |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Packaging and storage |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
USP Reference standards <11> |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Identification |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Heavy Metals, Method II <231> |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Loss on drying <731> |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Melting range, Class I <741> |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Residue on ignition <281> |
|
| DEHYDROACETIC ACID PF 33(4) Pg. 703 |
Assay |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
Title |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
Definition |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
Packaging and storage |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
Labeling |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
USP Reference stadards |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
Identification |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
Uniformity of dosage units |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
Loss on drying |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
Related compounds |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 32(3) Pg. 784 |
Assay |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 33(5) Pg. 903 |
Title |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 33(5) Pg. 903 |
Definition |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 33(5) Pg. 903 |
Labeling |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 33(5) Pg. 903 |
Loss on drying <731> |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 33(5) Pg. 903 |
Acid-neutralizing capacity <301> |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 33(5) Pg. 903 |
Related compounds |
|
| DIDANOSINE TABLETS FOR ORAL SUSPENSION
PF 33(5) Pg. 903 |
Assay |
|
| DILTIAZEM HYDROCHLORIDE PF 33(5) Pg. 907 |
Definition |
|
| DIMENHYDRINATE INJECTION PF 33(5) Pg.
907 |
USP Reference standards <11> |
|
| DIMENHYDRINATE INJECTION PF 33(5) Pg.
907 |
Identification |
|
| DIMENHYDRINATE PF 33(5) Pg. 907 |
Identification |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
Title |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
Definition |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
Packaging and storage |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
Labeling |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
USP Reference standards <11> |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
Identification |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
Bacterial endotoxins <85> |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
Sterility <71> |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
pH <791> |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
Other requirements |
|
| DINOPROST TROMETHAMINE INJECTION PF
33(5) Pg. 908 |
Assay |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Title |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Definition |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Packaging and storage |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Labeling |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
USP Reference standards |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Identification A, B, C |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Clarity |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Color |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
pH |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Benzyl alcohol content |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Free sulfate content |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Anti-factor IIa activity |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Anti-factor Xa to anti-factor IIa ratio |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Other requirements - Sterility Tests <71> |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Other requirements |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Assay (anti-factor Xa activity) |
|
| ENOXAPARIN SODIUM INJECTION PF 31(3) Pg.
761 |
Bacterial endotoxins |
|
| ENOXAPARIN SODIUM INJECTION PF 33(1) Pg.
58 |
Definition |
|
| ENOXAPARIN SODIUM INJECTION PF 33(1) Pg.
58 |
Appearance of solution (Clarity and degree of color of liquids) |
|
| ENOXAPARIN SODIUM INJECTION PF 33(1) Pg.
58 |
Benzyl alcohol content (if present) |
|
| ENOXAPARIN SODIUM INJECTION PF 33(1) Pg.
58 |
Bacterial endotoxins <85> |
|
| ENOXAPARIN SODIUM INJECTION PF 33(1) Pg.
58 |
Free sulfate content |
|
| ENOXAPARIN SODIUM INJECTION PF 33(1) Pg.
58 |
Assay (anti-factor Xa activity) |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Title |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Chemical structure |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
CAS number |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Definition |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Packaging and storage |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
USP Reference standards |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Identification A, B, C, D, E |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Appearance of solution |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Specific absorbance |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
pH |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Loss on drying |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Nitrogen content |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Heavy metals |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Sodium content |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Molar ratio of sulfate to carboxylate |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Benzyl alcohol content |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Anti-factor IIa activity |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Assay (anti-factor Xa activity) |
|
| ENOXAPARIN SODIUM PF 29(6) Pg. 1876 |
Bacterial endotoxins |
|
| ENOXAPARIN SODIUM PF 33(1) Pg. 52 |
Definition |
|
| ENOXAPARIN SODIUM PF 33(1) Pg. 52 |
USP Reference standards <11> |
|
| ENOXAPARIN SODIUM PF 33(1) Pg. 52 |
Identification |
|
| ENOXAPARIN SODIUM PF 33(1) Pg. 52 |
Appearance of solution (Clarity and degree of color of liquids) |
|
| ENOXAPARIN SODIUM PF 33(1) Pg. 52 |
pH <791> |
|
| ENOXAPARIN SODIUM PF 33(1) Pg. 52 |
Molar ratio of sulfate to carboxylate (see Chromatography <621>) |
|
| ENOXAPARIN SODIUM PF 33(1) Pg. 52 |
Benzyl alcohol content |
|
| ENOXAPARIN SODIUM PF 33(1) Pg. 52 |
Anti-factor IIa activity |
|
| ENOXAPARIN SODIUM PF 33(1) Pg. 52 |
Assay (anti-factor Xa activity) |
|
| ESTRADIOL AND NORETHINDRONE ACETATE
TABLETS PF 31(5) Pg. 1364 |
Dissolution |
|
| ESTRADIOL AND NORETHINDRONE ACETATE
TABLETS PF 33(2) Pg. 220 |
Dissolution |
|
| ETHINYL ESTRADIOL TABLETS PF 31(4) Pg.
1067 |
Disintegration |
|
| ETHIONAMIDE PF 33(4) Pg. 648 |
Assay |
|
| FAMOTIDINE TABLETS PF 33(4) Pg. 649 |
Dissolution <711> |
|
| FORMALDEHYDE SOLUTION PF 33(4) Pg. 650 |
Definition |
|
| FORMALDEHYDE SOLUTION PF 33(4) Pg. 650 |
Labeling |
|
| FORMALDEHYDE SOLUTION PF 33(4) Pg. 650 |
Content of methanol |
|
| FORMALDEHYDE SOLUTION PF 33(4) Pg. 650 |
Assay |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Title |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Chemical Info |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Definition |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Packaging and storage |
|
| FULVESTRANT PF 33(5) Pg. 909 |
USP Reference standards <11> |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Identification |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Specific rotation <781S> |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Water, Method Ic <921> |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Residue on ignition <281> |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Related compounds |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Diastereoisomer ratio |
|
| FULVESTRANT PF 33(5) Pg. 909 |
Assay |
|
| GAMMA CYCLODEXTRIN PF 31(3) Pg. 812 |
Microbial limits |
|
| GAMMA CYCLODEXTRIN PF 31(3) Pg. 812 |
Title |
|
| GAMMA CYCLODEXTRIN PF 31(3) Pg. 812 |
Molecular weight |
|
| GAMMA CYCLODEXTRIN PF 31(3) Pg. 812 |
Packaging and storage |
|
| GAMMA CYCLODEXTRIN PF 31(3) Pg. 812 |
Identification A, B, C |
|
| GAMMA CYCLODEXTRIN PF 31(3) Pg. 812 |
Specific rotation |
|
| GAMMA CYCLODEXTRIN PF 31(3) Pg. 812 |
Loss on drying |
|
| GAMMA CYCLODEXTRIN PF 31(3) Pg. 812 |
Residue on ignition |
|
| GAMMA CYCLODEXTRIN PF 31(3) Pg. 812 |
Heavy metals |
|
| GAMMA CYCLODEXTRIN PF 33(4) Pg. 707 |
Chemical Info |
|
| GAMMA CYCLODEXTRIN PF 33(4) Pg. 707 |
Definition |
|
| GAMMA CYCLODEXTRIN PF 33(4) Pg. 707 |
USP Reference standards <11> |
|
| GAMMA CYCLODEXTRIN PF 33(4) Pg. 707 |
Color and clarity of solution |
|
| GAMMA CYCLODEXTRIN PF 33(4) Pg. 707 |
Related compounds |
|
| GAMMA CYCLODEXTRIN PF 33(4) Pg. 707 |
Reducing substances |
|
| GAMMA CYCLODEXTRIN PF 33(4) Pg. 707 |
Assay |
|
| GLUCOSAMINE HYDROCHLORIDE PF 33(4) Pg.
691 |
Specific rotation <781S> |
|
| GLUCOSAMINE SULFATE POTASSIUM CHLORIDE
PF 33(4) Pg. 692 |
Identification |
|
| GLUCOSAMINE SULFATE POTASSIUM CHLORIDE
PF 33(4) Pg. 692 |
Specific rotation <781S> |
|
| GLUCOSAMINE SULFATE POTASSIUM CHLORIDE
PF 33(4) Pg. 692 |
Residue on ignition <281> |
|
| GLUCOSAMINE SULFATE SODIUM CHLORIDE PF
33(4) Pg. 692 |
Identification |
|
| GLUCOSAMINE SULFATE SODIUM CHLORIDE PF
33(4) Pg. 692 |
Specific rotation <781S> |
|
| GLUCOSAMINE SULFATE SODIUM CHLORIDE PF
33(4) Pg. 692 |
Residue on ignition <281> |
|
| HYDROCODONE BITARTRATE AND HOMATROPINE
METHYLBROMIDE TABLETS PF 33(4) Pg. 654 |
Labeling |
|
| HYDROCODONE BITARTRATE AND HOMATROPINE
METHYLBROMIDE TABLETS PF 33(4) Pg. 654 |
Dissolution <711> |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Title |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Chemical Info |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Definition |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Packaging and storage |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Identification |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Limit of chloride |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Limit of lead |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Water-dispersible substances |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Loss on ignition <733> |
|
| HYDROPHOBIC COLLOIDAL SILICA PF 33(5)
Pg. 976 |
Assay |
|
| HYOSCYAMINE SULFATE PF 33(4) Pg. 659 |
Specific rotation <781S> |
|
| INOSITOL PF 33(4) Pg. 711 |
Title |
|
| INOSITOL PF 33(4) Pg. 711 |
Chemical Info |
|
| INOSITOL PF 33(4) Pg. 711 |
Definition |
|
| INOSITOL PF 33(4) Pg. 711 |
Packaging and storage |
|
| INOSITOL PF 33(4) Pg. 711 |
USP Reference standards <11> |
|
| INOSITOL PF 33(4) Pg. 711 |
Clarity of solution |
|
| INOSITOL PF 33(4) Pg. 711 |
Color of solution |
|
| INOSITOL PF 33(4) Pg. 711 |
Identification |
|
| INOSITOL PF 33(4) Pg. 711 |
Conductivity |
|
| INOSITOL PF 33(4) Pg. 711 |
Water, Method I <921> |
|
| INOSITOL PF 33(4) Pg. 711 |
Barium |
|
| INOSITOL PF 33(4) Pg. 711 |
Limit of lead |
|
| INOSITOL PF 33(4) Pg. 711 |
Related compounds |
|
| INOSITOL PF 33(4) Pg. 711 |
Assay |
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE
TABLETS PF 33(4) Pg. 659 |
Dissolution <711> |
|
| ISOTRETINOIN CAPSULES PF 33(4) Pg. 666 |
Dissolution <711> |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Title |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Definition |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Packaging and storage |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Labeling |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
USP Reference standards <11> |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Identification |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Bacterial endotoxins <85> |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Sterility <71> |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Other requirements |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Assay for ivermectin |
|
| IVERMECTIN AND CLORSULON INJECTION PF
33(5) Pg. 921 |
Assay for clorsulon |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Title |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Definition |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Packaging and storage |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Labeling |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
USP Reference standards <11> |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Identification |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Bacterial endotoxins <85> |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Sterility <71> |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Chromatographic purity |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Other requirements |
|
| IVERMECTIN INJECTION PF 33(5) Pg. 913 |
Assay |
|
| IVERMECTIN PASTE PF 33(5) Pg. 914 |
Title |
|
| IVERMECTIN PASTE PF 33(5) Pg. 914 |
Definition |
|
| IVERMECTIN PASTE PF 33(5) Pg. 914 |
Packaging and storage |
|
| IVERMECTIN PASTE PF 33(5) Pg. 914 |
Labeling |
|
| IVERMECTIN PASTE PF 33(5) Pg. 914 |
USP Reference standards <11> |
|
| IVERMECTIN PASTE PF 33(5) Pg. 914 |
Identification |
|
| IVERMECTIN PASTE PF 33(5) Pg. 914 |
Chromatographic purity |
|
| IVERMECTIN PASTE PF 33(5) Pg. 914 |
Assay |
|
| IVERMECTIN PF 33(5) Pg. 912 |
Definition |
|
| IVERMECTIN TABLETS PF 33(5) Pg. 918 |
Title |
|
| IVERMECTIN TABLETS PF 33(5) Pg. 918 |
Definition |
|
| IVERMECTIN TABLETS PF 33(5) Pg. 918 |
Packaging and storage |
|
| IVERMECTIN TABLETS PF 33(5) Pg. 918 |
USP Reference standards <11> |
|
| IVERMECTIN TABLETS PF 33(5) Pg. 918 |
Identification |
|
| IVERMECTIN TABLETS PF 33(5) Pg. 918 |
Uniformity of dosage units <905> |
|
| IVERMECTIN TABLETS PF 33(5) Pg. 918 |
Limit of 8a-oxo-H2B1a |
|
| IVERMECTIN TABLETS PF 33(5) Pg. 918 |
Assay |
|
| IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg.
916 |
Title |
|
| IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg.
916 |
Definition |
|
| IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg.
916 |
Packaging and storage |
|
| IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg.
916 |
Labeling |
|
| IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg.
916 |
USP Reference standards <11> |
|
| IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg.
916 |
Identification |
|
| IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg.
916 |
Chromatographic purity |
|
| IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg.
916 |
Assay |
|
| LIGHT MINERAL OIL PF 33(5) Pg. 972 |
Definition |
|
| LIGHT MINERAL OIL PF 33(5) Pg. 972 |
Packaging and storage |
|
| LIGHT MINERAL OIL PF 33(5) Pg. 972 |
Labeling |
|
| LIGHT MINERAL OIL PF 33(5) Pg. 972 |
USP Reference standards <11> |
|
| LIGHT MINERAL OIL PF 33(5) Pg. 972 |
Identification |
|
| LIGHT MINERAL OIL PF 33(5) Pg. 972 |
Viscosity <911> |
|
| LIGHT MINERAL OIL PF 33(5) Pg. 972 |
Acidity,Readily carbonizable substances, Limit of polycyclic aromatic hydrocarbons, Limit of sulfur compounds, and Solid paraffin |
|
| MAGALDRATE AND SIMETHICONE ORAL
SUSPENSION PF 33(5) Pg. 923 |
Defoaming activity |
|
| MAGALDRATE AND SIMETHICONE TABLETS PF
33(5) Pg. 923 |
Defoaming activity |
|
| MAGALDRATE AND SIMETHICONE TABLETS PF
33(5) Pg. 923 |
Defoaming activity |
|
| MEFLOQUINE HYDROCHLORIDE PF 33(4) Pg.
667 |
Assay |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Chemical Info |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Definition |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Packaging and storage |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Labeling |
|
| MINERAL OIL PF 33(5) Pg. 962 |
USP Reference standards <11> |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Identification |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Neutrality |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Acidity |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Readily carbonizable substances |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Limit of polycyclic aromatic hydrocarbons |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Limit of sulfur compounds |
|
| MINERAL OIL PF 33(5) Pg. 962 |
Viscosity |
|
| MINERAL OIL, RECTAL PF 33(5) Pg. 964 |
Packaging and storage |
|
| MINERAL OIL, RECTAL PF 33(5) Pg. 964 |
USP Reference standards <11> |
|
| MINERAL OIL, RECTAL PF 33(5) Pg. 964 |
Identification |
|
| MINERAL OIL, RECTAL PF 33(5) Pg. 964 |
Viscosity |
|
| MINERAL OIL, RECTAL PF 33(5) Pg. 964 |
Neutrality |
|
| MINERAL OIL, RECTAL PF 33(5) Pg. 964 |
Acidity |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Title |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Chemical Info |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Definition |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Packaging and storage |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
USP Reference standards <11> |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Identification |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Melting range, Class Ia <741> |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Loss on drying <731> |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Residue on ignition <281> |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Heavy metals, Method II <231> |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Related compounds |
|
| MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924 |
Assay |
|
| NAPHAZOLINE HYDROCHLORIDE OPHTHALMIC
SOLUTION PF 33(5) Pg. 926 |
Assay |
|
| NICOTINE TRANSDERMAL SYSTEM PF 33(5) Pg.
927 |
Drug release <724> |
|
| NICOTINE TRANSDERMAL SYSTEM PF 33(5) Pg.
927 |
Assay |
|
| NORETHINDRONE TABLETS PF 32(6) Pg. 1736 |
Labeling |
|
| NORETHINDRONE TABLETS PF 32(6) Pg. 1736 |
Disintegration <701> |
|
| NORETHINDRONE TABLETS PF 33(3) Pg. 432 |
Dissolution <711> |
|
